Accelerating the digital revolution in life sciences.

Portfolio companies

We partner with entrepreneurs, academics, and engineers to turn their groundbreaking ideas into dominant businesses that span the tech and bio ecosystem.
Text Link

Kimia Therapeutics

Developing a drug discovery engine using Chemotype Evolution to generate extensive datasets.

Text Link

Automata

Next-generation lab automation and data management

Text Link

Enveda Biosciences

Unlocking the planet's chemistry to discover next-generation therapies

Text Link

Lamin

Open-source software infrastructure for the modern lab

Text Link

NewLimit

Treating age-related disease to extend human healthspan.

Text Link

Stealth

Biologics Manufacturing Platform

Text Link

Kaleidoscope Bio

Software to supercharge how scientific teams collaborate, manage experiments, and track decision-making

Search open roles at our portfolio companies

view job board
The Generalist: Zavain Dar, GP at Dimension on investing at the bleeding edge of technology and life sciences
The Generalist

Investing at the bleeding edge of technology and life sciences.

Once More Unto the Breach, Dear Friends
Substack: Dimension Research

Building out a research practice at Dimension.

Coinbase founder Brian Armstrong raises $40 million for NewLimit, a startup that wants to ‘cure aging’
Fortune

Coinbase founder Brian Armstrong raises $40 million for NewLimit, a startup that wants to ‘cure aging’

NewLimit, cofounded by Coinbase CEO Brian Armstrong, raises $40M to extend life
TechCrunch

NewLimit, cofounded by Coinbase CEO Brian Armstrong, raises $40M to extend life

NewLimit Series A
NewLimit Blog

NewLimit has secured $40 million in Series A funding from Dimension, Founders Fund, and Kleiner Perkins with participation from Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam

Eric Newcomer: A New Dimension
Dead Cat Podcast

I wanted to hear why Goulburn and Dar, general partners at Lux Capital, and Li, a general partner at Obvious Ventures, decided to embark on the long, hard trek of building their own firm.

New York Bio Breakfast Series
New York Bio

NewYork BIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient engagement and more cutting topics across the biopharmaceutical industry.

Homeroom Podcast : Adam Goulburn
Homeroom Podcast

Adam Goulburn is the co-founder and Managing Partner of Dimension, a $300 million fund focused on investing in companies at the intersection of medicine and data science.

New VC Firm Dimension Gets $350 Million as Healthcare Venture Fundraising Remains High
Wall Street Journal

New VC Firm Dimension Gets $350 Million as Healthcare Venture Fundraising Remains High

Three venture investors weigh in on the future of biotech as they launch a new $350M fund
Fortune

Three venture investors weigh in on the future of biotech as they launch a new $350M fund

As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M
BioSpace

As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M
Fierce Biotech

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M

Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’
BioPharma Dive

Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’

Focused exclusively on life sciences, three top investors set out on their own
STAT

Focused exclusively on life sciences, three top investors set out on their own

‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences
Endpoints

‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences

Dimension Debuts With 350M To Back Startups That Digitize Biology
Timmerman Report

Dimension Debuts With 350M To Back Startups That Digitize Biology

These Venture Veterans Have Launched A $350 Million Fund Aimed At Digitizing Life Sciences
Forbes

These Venture Veterans Have Launched A $350 Million Fund Aimed At Digitizing Life Sciences

Kaleidoscope Metadata

Metadata: The 'How' and 'Why' Behind Your Science

Enveda Series B Announcement
Endpoints

Enveda secures $68M to move revised pipeline into the clinic in 2023

Enveda Natural Product
MedCity News

Here’s a look at natural product drug discovery 2.0

Kaleidoscope Seed Announcement
Endpoints

'Structure, beauty and clarity': With seed financing, Kaleidoscope aims to synchronize R&D teams

Kaleidoscope Seed Announcement 2
AlleyWatch

Kaleidoscope Raises $6M for its Collaboration Platform for Research Science Teams